Kim ES, Keam SJ, et al.
Drugs. Date of publication 2017 Mar 1;volume 77(3):345-352.
1. Drugs. 2017 Mar;77(3):345-352. doi: 10.1007/s40265-017-0703-7.
Teduglutide: A Review in Short Bowel Syndrome.
Kim ES(1), Keam SJ(2).
Author information:
(1)Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand.
demail@springer.com.
(2)Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand.
Subcutaneous teduglutide (Revestive®), a glucagon-like peptide-2 analogue that
increases intestinal absorption, is approved in the EU for the treatment of short
bowel syndrome (SBS) in patients aged ≥1 year who are stable following a period
of postsurgical intestinal adaptation. In a phase III trial in adults with SBS
intestinal failure (IF) dependent on parenteral support (PS), a significantly
greater proportion of teduglutide 0.05 mg/kg/day than placebo recipients achieved
a ≥20% reduction in weekly PS volume from baseline to week 20 and maintained it
to week 24. The proportion of patients who had a reduction in one or more days on
PS was also significant with teduglutide compared with placebo. Improved
intestinal absorption and reduced PS requirements were generally maintained in
the longer term. Results from a phase III trial in paediatric patients with
SBS-IF dependent on PS were consistent with those in adults. Adverse events were
mostly of mild to moderate severity and generally consistent with the underlying
condition or known mechanism of the drug (e.g. central line-related issues,
gastrointestinal events). Teduglutide is therefore a useful treatment option in
children (aged ≥1 year), adolescents and adults with SBS.
DOI: 10.1007/s40265-017-0703-7
PMID: 28194723 [Indexed for MEDLINE]
Appears in following Topics:
